What Glucagon is
Glucagon is an endogenous peptide hormone that raises blood glucose through hepatic metabolic signaling and is also used in approved emergency and diagnostic contexts.
Glucagon is grouped under Endogenous / Biology / Approved / Clinical / Fat Loss + GLP-1s on PeptideFactCheck because it is essential to understand next-generation metabolic peptides that combine GLP-1, GIP, and glucagon receptor activity.
The useful starting point is to separate the molecule itself from the internet story around it. It matters because retatrutide-style drugs include glucagon receptor activity.
Why people keep looking it up
People connect glucagon with raising blood sugar and the new triple-agonist weight-loss drugs.
Glucagon is a peptide hormone that tells the liver to release glucose and affects metabolic state.
Glucagon tends to stay in the conversation because it touches a familiar public theme: glucagon receptor, glucose release, and metabolism. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Endogenous glucagon, approved glucagon products, and investigational glucagon agonist combinations are different categories.
Human physiology, clinical use, and official labels support its established roles.
Mechanistic biology is deeply established.
Why this page carries the current tier: Approved medicine and central endogenous peptide hormone.
The current seed trail for Glucagon is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Context matters: endogenous physiology, approved medicines, and investigational agonist combinations are not interchangeable.
FDA-approved glucagon products exist with official labels.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Glucagon. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Glucagon is CID 16132283. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16132283
- Formula
- C153H225N43O49S
- Molecular weight
- 3482.7
- InChIKey
- MASNOZXLGMXCHN-ZLPAWPGGSA-N
Matched synonyms include Glucagonum, Glucagone, Glukagon Novo, Glucagon, pig, 76LA80IG2G, CHEBI:5391, Glucagon, porcine, for bioassay, Glukagon.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Glucagon returns 1412 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Glucagon returns 64984 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Glucagon
- Generic names
- GLUCAGON
- Routes
- Not linked
- Application numbers
- ANDA204468
Indications and usage. 1 INDICATIONS AND USAGE Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: • for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. ( 1.1 ) • as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injec...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Substantial Increase in Blood Pressure in Patients with Pheochromocytoma : Contraindicated in patients with pheochromocytoma because Glucagon for Injection may stimulate the release of catecholamines from the tumor. ( 4 , 5.1 ) • Hypoglycemia in Patients with Insulinoma : In patients with insulinoma, glucagon administration may produce an initial increase in blood glucose; however, Gluca...
Contraindications. 4 CONTRAINDICATIONS Glucagon for Injection is contraindicated in patients with: • Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warning and Precautions (5.1) ] • Insulinoma because of the risk of hypoglycemia [see Warning and Precautions (5.2) ] • Known hypersensitivity to glucagon or any of the excipients in Glucagon for Injection. Allergic reactions have been reported with glu...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.